PGPooja Gangras

Pooja Gangras

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Pooja Gangras has a total of 11 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Quantification of mRNA Decay Rates in HeLa and SH-SY5Y Cell Lines Reveals Novel Properties of Membrane Protein Coding Transcripts

    by Melanie B. Martinez, Colton J. Williamson, Tareian Cazares, Chunlao Tang, Marjoke F. Debets, Pooja Gangras

    Posttranscriptional regulation is crucial for siRNA design, as decay rates in cell lines influence perceived siRNA potency. This study profiles transcripts with 'fast' and 'slow' half-lives in HeLa and SH-SY5Y cells, commonly used in drug discovery. We calculated half-lives for 1,815 HeLa and 5,376 SH-SY5Y transcripts, finding comparable half-lives between cell lines, though HeLa cells generally had longer half-lives. Comparing mRNA and protein half-lives, 'fast' decay transcripts encoded proteins with shorter half-lives, while 'slow' decay transcripts encoded stable proteins. We linked mRNA decay rates to siRNA activity by comparing HeLa data to a previous siRNA screen, discovering that faster decay transcripts had lower knockdown. Surprisingly, stable transcripts, more amenable to knockdown, were over-represented by membrane protein-coding transcripts. Despite their stability, these transcripts had low-to-moderate expression, regardless of miRNA regulation. We explored cis- and trans- features affecting mRNA stability and expression, suggesting that low RNA binding protein (RBP) binding, combined with specific stabilizing RBP regulation, contributes to the stability of these membrane protein-coding transcripts. This study highlights the importance of understanding transcript features, mRNA decay and its potential impact on siRNA efficacy, particularly for transcripts encoding membrane proteins.


  • Open Access

    Investigating SH-SY5Y Neuroblastoma Cell Surfaceome as a Model for Neuronal-Targeted Novel Therapeutic Modalities

    by Pooja Gangras, Valentina Gelfanova, Graham D. Williams, Samuel K. Handelman, Ryan M. Smith, Marjoke F. Debets

    The SH-SY5Y neuroblastoma cells are a widely used in vitro model approximating neurons for testing the target engagement of therapeutics designed for neurodegenerative diseases and pain disorders. However, their potential as a model for receptor-mediated delivery and uptake of novel modalities, such as antibody-drug conjugates, remains understudied. Investigation of the SH-SY5Y cell surfaceome will aid in greater in vitro to in vivo correlation of delivery and uptake, thereby accelerating drug discovery. So far, the majority of studies have focused on total cell proteomics from undifferentiated and differentiated SH-SY5Y cells. While some studies have investigated the expression of specific proteins in neuroblastoma tissue, a global approach for comparison of neuroblastoma cell surfaceome to the brain and dorsal root ganglion (DRG) neurons remains uninvestigated. Furthermore, an isoform-specific evaluation of cell surface proteins expressed on neuroblastoma cells remains unexplored. In this study, we define a bioinformatic workflow for the identification of high-confidence surface proteins expressed on brain and DRG neurons using tissue proteomic and transcriptomic data. We then delineate the SH-SY5Y cell surfaceome by surface proteomics and show that it significantly overlaps with the human brain and DRG neuronal surface proteome. We find that, for 32% of common surface proteins, SH-SY5Y-specific major isoforms are alternatively spliced, maintaining their protein-coding ability, and are predicted to localize to the cell surface. Validation of these isoforms using surface proteomics confirms a SH-SY5Y-specific alternative NRCAM (neuron-glia related cell adhesion molecule) isoform, which is absent in typical brain neurons, but present in neuroblastomas, making it a receptor of interest for neuroblastoma-specific therapeutics.


  • surfaltr: An R/Bioconductor package to benchmark surface protein isoforms by rapid prediction and visualization of transmembrane topologies

    by Pooja Gangras, Aditi Merchant

    Cell surface proteins form a major fraction of the druggable proteome and can be used for tissue‐specific delivery of oligonucleotide/cell‐based therapeutics. Surface protein isoforms are regulated by alternative splicing, which drives subcellular localization and transmembrane (TM) topology thereby shaping cell type specific signatures. Current advances in multiomic approaches have developed interest in discovery of tissue‐specific alternatively spliced or novel surface protein isoforms. However, there exists a need for bioinformatic approaches for rapidly benchmarking the large number of isoforms identified by these approaches. To address this gap, we have developed, surfaltr, an R package which takes user input isoforms, pairs them with the known principal isoform of the gene, predicts TM topologies, and generates a customizable graphical output. Further, surfaltr facilitates prioritization of topologically diverse isoform pairs through incorporation of three different ranking metrics and through protein alignment functions. Here, we demonstrate the utility of our R package by evaluating the mouse retina‐specific novel surface protein isoforms identified in Ray et al. 2020. surfaltr is freely available through Bioconductor (https://bioconductor.org/packages/surfaltr) and the vignette provides extensive instructions for implementation.